Resona Asset Management Co. Ltd. acquired a new position in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 92,122 shares of the medical instruments supplier's stock, valued at approximately $20,930,000.
A number of other hedge funds and other institutional investors have also bought and sold shares of BDX. Wesbanco Bank Inc. grew its holdings in shares of Becton, Dickinson and Company by 1.9% in the 4th quarter. Wesbanco Bank Inc. now owns 2,558 shares of the medical instruments supplier's stock valued at $580,000 after acquiring an additional 48 shares in the last quarter. S.A. Mason LLC increased its stake in shares of Becton, Dickinson and Company by 3.7% during the 4th quarter. S.A. Mason LLC now owns 1,414 shares of the medical instruments supplier's stock worth $321,000 after purchasing an additional 50 shares during the last quarter. Hillsdale Investment Management Inc. lifted its stake in Becton, Dickinson and Company by 1.7% in the 4th quarter. Hillsdale Investment Management Inc. now owns 3,060 shares of the medical instruments supplier's stock valued at $694,000 after purchasing an additional 50 shares during the last quarter. Americana Partners LLC grew its holdings in Becton, Dickinson and Company by 3.5% during the fourth quarter. Americana Partners LLC now owns 1,520 shares of the medical instruments supplier's stock worth $345,000 after purchasing an additional 52 shares during the period. Finally, Picton Mahoney Asset Management raised its stake in Becton, Dickinson and Company by 61.4% in the fourth quarter. Picton Mahoney Asset Management now owns 142 shares of the medical instruments supplier's stock valued at $32,000 after buying an additional 54 shares during the period. Institutional investors and hedge funds own 86.97% of the company's stock.
Insider Buying and Selling
In other news, EVP Michael David Garrison sold 479 shares of the stock in a transaction on Wednesday, April 9th. The shares were sold at an average price of $197.28, for a total transaction of $94,497.12. Following the completion of the sale, the executive vice president now directly owns 4,887 shares in the company, valued at $964,107.36. This represents a 8.93 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Richard Byrd sold 1,940 shares of the business's stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $224.91, for a total transaction of $436,325.40. Following the completion of the transaction, the executive vice president now owns 7,411 shares in the company, valued at approximately $1,666,808.01. The trade was a 20.75 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 4,675 shares of company stock worth $1,057,182 in the last ninety days. Company insiders own 0.36% of the company's stock.
Wall Street Analysts Forecast Growth
A number of equities research analysts recently weighed in on BDX shares. Barclays dropped their price target on Becton, Dickinson and Company from $279.00 to $261.00 and set an "overweight" rating on the stock in a research note on Monday. StockNews.com upgraded shares of Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a research note on Wednesday, April 2nd. Finally, Piper Sandler boosted their price objective on Becton, Dickinson and Company from $275.00 to $280.00 and gave the stock an "overweight" rating in a report on Tuesday, January 28th. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus target price of $275.71.
Get Our Latest Report on BDX
Becton, Dickinson and Company Price Performance
Shares of BDX stock traded down $0.34 on Friday, reaching $198.78. The company had a trading volume of 524,426 shares, compared to its average volume of 1,677,814. The stock has a market capitalization of $57.08 billion, a PE ratio of 33.04, a price-to-earnings-growth ratio of 1.63 and a beta of 0.35. The company has a quick ratio of 0.63, a current ratio of 1.13 and a debt-to-equity ratio of 0.69. The business's 50-day moving average is $224.78 and its 200 day moving average is $230.09. Becton, Dickinson and Company has a one year low of $193.03 and a one year high of $251.99.
Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last announced its quarterly earnings results on Wednesday, February 5th. The medical instruments supplier reported $3.43 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.00 by $0.43. Becton, Dickinson and Company had a net margin of 8.47% and a return on equity of 15.74%. Equities research analysts forecast that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.
Becton, Dickinson and Company declared that its Board of Directors has initiated a share repurchase program on Tuesday, January 28th that permits the company to repurchase 10,000,000 outstanding shares. This repurchase authorization permits the medical instruments supplier to purchase shares of its stock through open market purchases. Stock repurchase programs are generally an indication that the company's leadership believes its shares are undervalued.
Becton, Dickinson and Company Announces Dividend
The firm also recently disclosed a quarterly dividend, which was paid on Monday, March 31st. Investors of record on Monday, March 10th were issued a $1.04 dividend. The ex-dividend date of this dividend was Monday, March 10th. This represents a $4.16 dividend on an annualized basis and a yield of 2.09%. Becton, Dickinson and Company's dividend payout ratio (DPR) is presently 69.10%.
About Becton, Dickinson and Company
(
Free Report)
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.
Featured Articles
Before you consider Becton, Dickinson and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Becton, Dickinson and Company wasn't on the list.
While Becton, Dickinson and Company currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
